Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of Mix
Resolved · earnings · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-21. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
Accelerating revenue mix transition into non-patent-cliff commercial assets lifts BMY operating cash flow predictability and expands forward P/E multiples relative to the XLV benchmark.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factBristol Myers Squibb delivered $12.9 billion in Q2 revenue and 153% year-over-year EPS growth. |
| What else was confirmed? | Reported factThe company's newer drug growth portfolio now accounts for nearly 60% of total revenue, expanding 15% year-over-year. |
| Does the valuation support acting? | Interpretation1 stored valuation assumptions for BMY; the latest is dated 2026-08-06. |
| What would change the assessment? | UnknownBMY Next Quarterly Top-Line Progression — Track whether growth portfolio revenue maintains >15% annual growth run-rate. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Bristol Myers Squibb delivered $12.9 billion in Q2 revenue and 153% year-over-year EPS growth.
- · The company's newer drug growth portfolio now accounts for nearly 60% of total revenue, expanding 15% year-over-year.
- · BMY equity is up 17% year-to-date while continuing to trade at a discount to major biopharma peers.
Public research record
Research framework · page evidenceCompleted event assessment
patent-cliff mitigation supporting forward cash flow multiples
| Type | Claim | Scope |
|---|---|---|
| Assumption | Bristol Myers Squibb delivered $12.9 billion in Q2 revenue and 153% year-over-year EPS growth. | 2026-09-21 |
| Interpretation | patent-cliff mitigation supporting forward cash flow multiples | BMY |
Countercase, invalidators, and sources
Growth portfolio maintains double-digit expansion, driving multi-quarter consensus upward revisions.
- · BMY Next Quarterly Top-Line Progression — Track whether growth portfolio revenue maintains >15% annual growth run-rate.
- Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder · 2026-09-20
What remains unresolved
- Base path
- BMY consolidates recent 17% gains as growth assets balance patent expirations.
- Adverse path
- Regulatory pricing pressure or pipeline execution delays stall growth portfolio ramp.
- Supportive path
- Growth portfolio maintains double-digit expansion, driving multi-quarter consensus upward revisions.
- · BMY Next Quarterly Top-Line Progression — Track whether growth portfolio revenue maintains >15% annual growth run-rate.next month
Evidence
- Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder2026-09-20
“Bristol Myers Squibb (BMY) is up 17% this year and trades at a discount to peers despite strong Q2 performance with $12.9B revenue and 153% EPS growth. The company's growth portfolio of newer drugs now accounts for nearly 60% of revenue and grew 15% year-over-year”
Supports: BMY generated $12.9B revenue in Q2 with growth assets reaching ~60% of total revenue.